CORMEDIX INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
CORMEDIX INC. (CRMD) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $150.02 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- CORMEDIX INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $150.02M.
- CORMEDIX INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$19.07M.
- CORMEDIX INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$45.95M.
- CORMEDIX INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$29.97M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | $150.02M 10-K · filed 2026-03-05 | |
| 2024-12-31 | -$19.07M 10-K · filed 2026-03-05 | -$19.07M 10-K · filed 2025-03-25 |
| 2023-12-31 | -$45.95M 10-K · filed 2025-03-25 | |
| 2022-12-31 | -$29.97M 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |